DEFTA Partners — 2019 Investments
5 investments dated 2019 · listed companies and verified rows first · show all
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations.
BiotechFort Worth, US
Daniel Schmitt(President & Chief Executive Officer)Paul Lytle(Executive Officer)inAndrew Mazar(Executive Officer)
BoardTodd Thomson(Director)inRoger Sawhney(Director)Jason Keyes(Director)
Co-investorsBios PartnersIllinois VenturesKairos Venture Investments, LlcNuFund Venture GroupBiosTech Coast Angels
Actuate provides AI-based video analytics that turn existing IP cameras and NVRs into a security detection system, offering real-time alerts for threats such as intruders, loitering, guns, and crowds.
AI & Machine LearningCloud ComputingCybersecurityGovTechSaaS
Sonny Tai(Co-Founder)inKen Francis(CEO)in
Co-investorsBios PartnersBling CapitalDorm RoomGray Line PartnersMetaPropMetaProp Ventures+4 more
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+6 more
Co-investorsRethink Impact
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BioEclipse Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.





















